TRIM24 Protein Found to Control a Key Cancer Cell Immortality Mechanism

Telomere maintenance is essential for cellular immortality, and most cancers achieve this through telomerase. However, 10–15% of cancers — including many pediatric brain tumors and sarcomas — rely instead on Alternative Lengthening of Telomeres (ALT), a recombination-based mechanism that remains poorly understood and therapeutically underexplored. Understanding the molecular machinery driving ALT is critical both for cancer biology and for broader questions about genome stability and cellular aging.

To identify regulators of replication stress responses, the authors developed BLOCK-ID (BrdU-mediated Local Oligo-Capture and Kinase-Identified Discovery), a proteomic proximity-labeling approach designed to capture proteins accumulating at stalled or stressed replication forks in human cancer cells. Using this method, they identified a suite of known and novel replication stress responders, prominently including TRIM24, a RING-domain E3 ubiquitin ligase and bromodomain/PHD-containing chromatin reader that recognizes acetylated histones.

Functional studies demonstrated that TRIM24 is specifically enriched at ALT telomeres and is required for robust ALT activity. TRIM24 loss caused a significant reduction in ALT-associated PML bodies (APBs) — the membraneless organelles where ALT DNA synthesis occurs — and suppressed de novo telomere DNA synthesis as measured by multiple orthogonal assays including PFGE and telomere FISH. Mechanistically, TRIM24 recruitment to telomeres depended on the acetyltransferases p300 and CBP, which deposit acetyl marks on histones that TRIM24's bromodomain recognizes, establishing a histone acetylation-to-chromatin reader signaling axis at ALT telomeres.

Strikingly, when TRIM24 was artificially tethered directly to telomeres, it was sufficient to stimulate de novo telomere synthesis independently of p300/CBP activity and PML, bypassing the upstream chromatin signaling requirement. However, this tethering-induced telomere synthesis still required SUMOylation, indicating that SUMO-dependent steps operate downstream of TRIM24 recruitment and upstream of DNA synthesis. This places TRIM24 at a molecular switchboard integrating acetylation-reading and SUMO signaling to coordinate ALT.

The identification of this p300/CBP → histone acetylation → TRIM24 → SUMOylation → telomere synthesis pathway opens new therapeutic angles for ALT-dependent cancers. Because p300/CBP inhibitors and SUMO pathway inhibitors are already in clinical or preclinical development, disrupting this cascade represents a potentially actionable strategy. Moreover, the BLOCK-ID platform itself is a broadly applicable tool for future discovery of replication stress response factors.